Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute lymphoblastic leukemia.

Viana SS, Araujo GS, Faro GB, da Cruz-Silva LL, Araújo-Melo CA, Cipolotti R.

Rev Bras Hematol Hemoter. 2012;34(4):275-9. doi: 10.5581/1516-8484.20120071.

2.

Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.

Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, Zanesco L, Cesaro S.

Cancer. 2004 Aug 1;101(3):635-41.

3.

Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens.

Nilsson A, De Milito A, Engström P, Nordin M, Narita M, Grillner L, Chiodi F, Björk O.

Pediatrics. 2002 Jun;109(6):e91.

PMID:
12042585
4.

Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia.

Aytac S, Yalcin SS, Cetin M, Yetgin S, Gumruk F, Tuncer M, Yurdakok K, Gurgey A.

Pediatr Hematol Oncol. 2010 Aug;27(5):333-43. doi: 10.3109/08880011003767720.

PMID:
20469978
5.

Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12.

6.

Protection against vaccine preventable diseases in children treated for acute lymphoblastic leukemia.

de de la Fuente Garcia I, Coïc L, Leclerc JM, Laverdière C, Rousseau C, Ovetchkine P, Tapiéro B.

Pediatr Blood Cancer. 2017 Feb;64(2):315-320. doi: 10.1002/pbc.26187. Epub 2016 Oct 8.

PMID:
27718310
8.

Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia.

Ercan TE, Soycan LY, Apak H, Celkan T, Ozkan A, Akdenizli E, Kasapçopur O, Yildiz I.

J Pediatr Hematol Oncol. 2005 May;27(5):273-7.

PMID:
15891564
9.

Immune response to simultaneous administration of a combined measles, mumps and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine.

Giammanco G, Li Volti S, Salemi I, Giammanco Bilancia G, Mauro L.

Eur J Epidemiol. 1993 Mar;9(2):199-202.

PMID:
8519358
10.

Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.

Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E.

Pediatr Infect Dis J. 2013 Aug;32(8):889-97. doi: 10.1097/INF.0b013e318292f7b1.

PMID:
23538523
11.

Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.

Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M.

Vaccine. 2015 May 11;33(20):2379-86. doi: 10.1016/j.vaccine.2015.02.070. Epub 2015 Mar 9.

PMID:
25765966
12.

Prevalence of hepatitis B markers and measles, mumps, and rubella antibodies among Jewish refugees from the former Soviet Union.

Hurie MB, Gennis MA, Hernandez LV, Dindzans VJ, Davis JP.

JAMA. 1995 Mar 22-29;273(12):954-6.

PMID:
7884955
13.

Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.

Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR.

Pediatr Infect Dis J. 1996 Aug;15(8):687-92.

PMID:
8858673
14.

Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine.

Huang LM, Lee CY, Hsu CY, Huang SS, Kao CL, Wu FF, Lee CC, Chang HS, Huang LY.

Pediatr Infect Dis J. 1990 Jul;9(7):461-5.

PMID:
2371079
15.

Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.

D'Angio CT, Boohene PA, Mowrer A, Audet S, Menegus MA, Schmid DS, Beeler JA.

Pediatrics. 2007 Mar;119(3):e574-9.

PMID:
17332177
16.

Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer.

Bochennek K, Allwinn R, Langer R, Becker M, Keppler OT, Klingebiel T, Lehrnbecher T.

Vaccine. 2014 Jun 5;32(27):3357-61. doi: 10.1016/j.vaccine.2014.04.042. Epub 2014 Apr 29.

PMID:
24793952
17.

Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.

St Sauver JL, Dhiman N, Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Jacobsen SJ, Poland GA.

Hum Immunol. 2005 Jul;66(7):788-98.

PMID:
16112026
18.

Measles and rubella antibody status in children after treatment for acute lymphoblastic leukemia.

Volc SM, Almeida MT, Abadi MD, Cornacchioni AL, Odone Filho V, Cristofani LM.

J Pediatr (Rio J). 2006 Nov-Dec;82(6):481-4. Epub 2006 Sep 21.

19.
20.

Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.

Díaz-Ortega JL, Bennett JV, Castañeda-Desales D, Quintanilla DM, Martínez D, de Castro JF.

Vaccine. 2014 Jun 17;32(29):3680-6. doi: 10.1016/j.vaccine.2014.04.031. Epub 2014 May 14.

PMID:
24837512

Supplemental Content

Support Center